ad example

Month: October 2021

Hansen: Feds caved to Big Pharma, people got hurt

In April 2020, NIAID Director Anthony Fauci announced that antiviral remdesivir (sold by Gilead Sciences at $3,120 per patient for a treatment course) would become the standard of care for hospitalized COVID-19 patients. This decision came in spite of international studies proving that remdesivir does not provide significant clinical benefits.